Novartis (SWX: NOVN) reported earnings on April 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Novartis met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew slightly. Non-GAAP earnings per share expanded. GAAP earnings per share grew slightly.
Gross margins dropped, operating margins dropped, net margins expanded.
Novartis logged revenue of $14.02 billion. The eight analysts polled by S&P Capital IQ hoped for a top line of $13.99 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.32. The six earnings estimates compiled by S&P Capital IQ predicted $1.28 per share. Non-GAAP EPS of $1.32 for Q1 were 3.9% higher than the prior-year quarter's $1.27 per share. GAAP EPS of $0.97 for Q1 were 2.1% higher than the prior-year quarter's $0.95 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.6%, 30 basis points worse than the prior-year quarter. Operating margin was 20.4%, 120 basis points worse than the prior-year quarter. Net margin was 16.9%, 30 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $14.34 billion. On the bottom line, the average EPS estimate is $1.34.
Next year's average estimate for revenue is $57.32 billion. The average EPS estimate is $5.01.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Novartis is outperform, with an average price target of $70.42.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Novartis. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Novartis to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.